JANX250117P80000
- 37.00
- +19.30+109.04%
Janux Therapeutics Newsroom
BTIG Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $105
Buy Rating for Janux Therapeutics Amidst Competitive Landscape and Advancements in Masked T-cell Engagers
LifeSci Capital Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $100
Janux Therapeutics Price Target Maintained With a $200.00/Share by Cantor Fitzgerald
Janux Therapeutics Analyst Ratings
BTIG Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100
BTIG Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Kura Oncology (KURA)
Scotiabank Maintains Janux Therapeutics(JANX.US) With Hold Rating, Raises Target Price to $62
TD Cowen Remains a Buy on Janux Therapeutics Inc (JANX)
Janux Therapeutics Inc's Promising Data and Strategic Advancements Earn a Reiterated Buy Rating
Scotiabank Maintains Sector Perform on Janux Therapeutics, Raises Price Target to $62
Janux Therapeutics Price Target Raised to $91.00/Share From $79.00 by Leerink Partners
Janux Therapeutics Is Maintained at Outperform by Leerink Partners
Scotiabank Raises Price Target on Janux Therapeutics to $62 From $42, Keeps Sector Perform Rating
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Raises Target Price to $70
HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Raises Price Target to $70
Janux Therapeutics Analyst Ratings
Buy Rating Affirmed for Janux Therapeutics Inc. Amid Promising Clinical Data and Strategic Advancements